Moving Towards a New Personalised Medicine Approach to Primary Prevention in Diabetes: The First Steps

Medicine & Life Sciences

1. Metformin 100%
2. CHF protocol 77%
3. Left Ventricular Hypertrophy 66%
4. Coronary Artery Disease 64%
5. Symporters 56%
6. empagliflozin 48%
7. Heart Failure 47%
8. Sodium Potassium Chloride Symporter Inhibitors 42%
9. Placebos 38%
10. Ventricular Remodeling 36%
11. Sodium 34%
12. Aortic Valve Stenosis 34%
13. Cross-Over Studies 28%
14. Coronary Disease 27%
15. Insulin Resistance 25%
16. Diabetes Mellitus 24%
17. Scotland 23%
18. Randomized Controlled Trials 23%
19. Anti-Inflammatory Agents 22%
20. Glucose 21%
21. Ethics 21%
22. Osmotic Diuretics 18%
23. Kidney 16%
24. BI605906 16%
25. Creatinine 16%
26. 2-(3-(4-ethoxybenzyl)-4-chlorophenyl)-6-hydroxymethyltetrahydro-2H-pyran-3,4,5-triol 16%
27. Type 2 Diabetes Mellitus 15%
28. Weight Loss 15%
29. Sodium-Glucose Transporter 2 Inhibitors 14%
30. Research Ethics 14%
31. Blood Pressure 13%
32. Natriuresis 13%
33. Cystatin C 13%
34. Secondary Care 12%
35. Diuretics 10%
36. Glomerular Filtration Rate 9%
37. Stroke Volume 9%
38. Albumins 8%
39. Cardiovascular Diseases 8%
40. Publications 8%
41. Alleles 8%
42. Neutrophils 8%
43. Hemodynamics 7%
44. Oxidative Stress 7%
45. Body Weight 7%
46. Urine 7%
47. Lymphocytes 7%
48. Biomarkers 6%
49. Fasting 6%
50. Pharmaceutical Preparations 6%
51. Cytokines 6%
52. Thiobarbituric Acid Reactive Substances 6%
53. Exercise Tolerance 6%
54. Vascular Stiffness 6%
55. Intention to Treat Analysis 6%
56. Diuresis 5%
57. Subcutaneous Fat 5%
58. Controlled Clinical Trials 5%
59. Glycated Hemoglobin A 5%
60. Therapeutics 5%
61. Body Composition 5%
62. Standard of Care 5%